PetVivo Holdings Inc. to Trade on OTCQX Best Market
PetVivo Holdings Inc. begins trading today on OTCQX under the symbol 'PETV.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
The OTCQX Market is designed for established, investor-focused U.S. and international companies. The OTCQX Market has 625 securities as of today, while the broader OTC Markets Group includes approximately 12,000 securities. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.
PetVivo's signature product, SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PetVivo's other innovative product, PrecisePRP, is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
'Qualifying to trade on the OTCQX Best Market is a significant milestone for our Company,' said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. 'This upgrade reflects our continued commitment to transparency, strong corporate governance, and delivering long-term value to our shareholders. Trading on OTCQX will enhance our visibility within the investment community and provide greater liquidity and accessibility for investors as we continue to execute on our strategic growth initiatives.'
For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/ , https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com .
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for equine and companion animals. The Company's strategy is to leverage human therapies for the treatment of equine and companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO PetVivo Holdings, Inc.
Email: [email protected]
(952) 405-6216
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
14 minutes ago
- The Verge
Tim Cook says Apple ‘must' figure out AI and ‘will make the investment to do it'
Apple CEO Tim Cook boasted about the potential of AI and the company's approach to developing it in a rare all-hands today that was reported on by Bloomberg. Apple has been slow to roll out some of its AI features and has stumbled with a planned AI-powered upgrade to Siri, which it delayed earlier this year. According to Bloomberg: The executive gathered staff at Apple's on-campus auditorium Friday in Cupertino, California, telling them that the AI revolution is 'as big or bigger' as the internet, smartphones, cloud computing and apps. 'Apple must do this. Apple will do this. This is sort of ours to grab,' Cook told employees, according to people aware of the meeting. 'We will make the investment to do it.' Cook also apparently pointed to how the company has 'rarely been first' in categories like personal computers, smartphones, tablets, and MP3 players but that Apple eventually made the 'modern' versions of those. 'This is how I feel about AI,' Cook said, Bloomberg reports. Software chief Craig Federighi also spoke, discussing the Siri delay and how the company originally wanted to build it with a 'hybrid architecture.' Under that plan, one system would take care of things Siri can now, and the other would be powered by LLMs, but 'we realized that approach wasn't going to get us to Apple quality,' he said. The new plan is to move everything to a new architecture. The all-hands follows Cook's comments ahead of an earnings call yesterday where he said that the company is 'open to' acquisitions to accelerate its roadmap. Apple has also lost some of its AI talent as part of Meta's 'superintelligence' hiring spree. Posts from this author will be added to your daily email digest and your homepage feed. See All by Jay Peters Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Apple Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
Business Wire
43 minutes ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Yahoo
an hour ago
- Yahoo
Applovin Corp (APP) Divests Gaming Subsidiaries in $400M Tripledot Deal
AppLovin Corporation (NASDAQ:APP) is one of the best AI stocks to buy, according to billionaire Stanley Druckenmiller. On July 1, AppLovin Corporation announced the successful sale of its mobile gaming subsidiaries to Tripledot Group Holdings and its affiliates, with the deal officially closing on June 30, 2025. A close-up shot of a businessperson typing on a mobile device, highlighting the company's mobile messaging application. The sale included $400 million in cash—paid directly after a last-minute agreement change—as well as Tripledot shares representing around 20% of its fully diluted equity. AppLovin subsidiaries Morocco, Inc. and AppLovin GmbH were part of the transaction, with Tripledot, Eton Games, and Tripledot Group Holdings listed as purchasers. The deal reinforces AppLovin's strategic shift, as the company, headquartered in Palo Alto and listed on Nasdaq under APP, continues to focus on its core software business. AppLovin Corporation (NASDAQ:APP) is a technology company that develops software to help businesses connect with their ideal customers and grow their audience. It provides solutions for mobile app marketing, monetization, and analytics. It also leverages AI to power its advertising and app monetization platform. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Best 52-Week High Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.
